Douglas Kerr

Doug Kerr, M.D., Ph.D., is the chief medical officer at Generation Bio. He previously served as vice president and global development team lead for neurology at the Shire, overseeing development and strategy across multiple clinical programs. Previously, Dr. Kerr held a variety of leadership roles at Biogen, including senior director of corporate strategy and portfolio management as well as director of the ALS Innovation Initiative. Dr. Kerr also served as the global medical lead for spinal muscular atrophy (SMA) at Biogen, leading to the approval of the first treatment for this disease. Dr. Kerr received his B.A. from Princeton University and his M.D./Ph.D. from Jefferson Medical College. He obtained his MBA from Northeastern University School of Business.